THU NOV 9th, 2023, 22:15 CET

RLS Global initiates strategic review process aiming to commercialize ChloraSolv

The RLS Global Board of Directors has resolved to initiate a strategic review process to enable the commercial roll out of ChloraSolv across European markets.

RLS Global announced earlier today that RLS Global and Convatec have agreed to terminate the collaboration agreement. RLS Global and Convatec have agreed that both parties will work jointly and with the common target to have a smooth handover from Convatec to RLS Global.

The RLS Global Board of Directors will consider all strategic options, including a partnership, a sale of the company, a sale of ChloraSolv, or a financial investment in RLS Global.

“The review process will be undertaken with immediate effect, and we have set no timeline for completion of this process”, says Lars Johansson, Chairman of the Board, RLS Global.
“Bringing ChloraSolv to patients will require resources and capital that RLS Global does not have as of today, and hence we are now initiating a strategic review process,” Lars Johansson continues.

RLS Global (publ) is obliged to make the information contained herein public pursuant to the EU market abuse regulation (MAR). The information was submitted for publication through the agency of the contact person, on 9 November 2023 at 22:15 CET.

RLS Global’s shares have been listed on the Nasdaq First North Growth Market since 17th May, 2017 and trading takes place under the short name RLS. Certified Adviser is Redeye Aktiebolag.

Lars Johansson, Chairman of the Board, RLS Global
Phone: +46 70 588 81 90

Roland Frösing, acting CEO, RLS Global
Phone: +46 723 20 61 00